Angiotensin receptor blockers in nephroprotection at patients with diabetes mellitus: focus on losartan


Cite item

Full Text

Abstract

Many large studies have provided strong evidence that there is an association of elevated BP with a risk for cardiovascular events (CVE),
such as stroke, myocardial infarction and heart failure. But none of the studies has indicated that a drug is more effective than another one
in reducing the risk for CVE and death. The article summarizes the available data on ramipril in hypertensive patients of high cardiovascular
risk. The results of studies demonstrate strong and long-lasting antihypertensive effect of losartan. Moreover, losartan treatment
decreases cardiovascular events rate, damage of target organs, atherosclerosis progression and new cases of diabetes mellitus. Losartan
shows both high efficacy and low adverse event rate.

References

  1. Дедов И.И., Викулова О.К., Сухарева О.Ю., Сунцов Ю.И. Скрининг диабетической нефропатии в Российской Федерации. Сахарный диабет и хроническая болезнь почек. М., 2009; гл. 4.2: 39-59.
  2. Retnakaran R, Cull CA, Thorne KI et al. Holman for the UKPDS Study Group. Risk Factors for Renal Dysfunction in Type 2 Diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55 (6): 1832-9.
  3. Renal Data System: USRDS 2003 Аnnual data report. Bethesda, MD, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
  4. European Dialysis and Transplant Association. Report on management of renal failure in Europe, XXVI, 1995. Nephrol Dial Transplant 1996; 11 (Suppl. 7): 1-32.
  5. Бикбов Б.Т., Томилина Н.А. О состоянии заместительной почечной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998-2005 гг. Нефрология и диализ. 2007; 9 (1): 6-85.
  6. Soler MJ, Lloveras J, Batlle D. Angiotensin converting enzyme 2 and its emerging role in the regulation of the renin angiotensin system. Med Clin (Barc) 2008; 131 (6): 230-6.
  7. Billet S, Aguilar F, Baudry C, Clauser E. Role of angiotensin II AT(1) receptor activation in cardiovascular diseases. Kidney Int 2008; 23: 1-6.
  8. Siragy HM. The role of the AT2 receptor in hypertension. Am J Hypertens 2000; 13 (5 Pt 2): 62S-7S.
  9. Dina R, Jafari M. Angiotensin II-receptor antagonists: An overview. Am J Health-Syst Pharm 2000; 57: 1231-41.
  10. FDA Advisory Committee recommends approval of CosaarR to delay progression of renal disease in type 2 diabetic patients with proteinuria. [Media Release]. 2002; 12.
  11. Zandbergen AA, Baggen MG, Lamberts SW et al. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med 2003; 139: 90-6.
  12. Tan KC, Chow WS, Ai VH et al. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes Metab Res Rev 2002; 18 (1): 71-6.
  13. Lozano JV, Llisterri JL, Aznar J, Redon J. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001; 16 (Suppl. 1): 85-9.
  14. Esmatjes E, FloresL, Inigo P et al. Effect of losartan on TGF-b1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001; 16 (Suppl. 1): 90-3.
  15. Lacourciere Y, Belanger A, Godin C et al. Long-term comparison of losartan and enalapril in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58: 762-9.
  16. Nielsen S, Dollerup J, Nielsen B et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997; 12 (Suppl. 2): 19-23.
  17. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-9.
  18. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
  19. Lindholm LH, Ibsen H, Dahlof B et al. Cardovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 1004-10.
  20. Lindholm LH, Dahlof B, Edelman JM et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003; 362: 619-20.
  21. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-9.
  22. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
  23. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood-pressure independent effect. Circulation 2002; 106: 672-8.
  24. Marino H, Hakeda M, Babazono T et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocer, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res 2008; 31: 657-64.
  25. Yusuf S, Teo KK, Pogue J et al. for the ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
  26. Guidelines Committee. 2003 European Society of hypertension - European Society of cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 83918 от 12.09.2022 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 83917 от 12.09.2022 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies